Souhaitez-vous accéder aux communiqués récents ?

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy...

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Avantor, Inc. (NYSE: AVTR), Baxter International...

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene...

SAN FRANCISCO, March 10, 2026 (GLOBE NEWSWIRE) -- DianaHR, which offers the first AI-powered HR-as-a-Service platform for SMBs, is proud to announce that its founder and CEO, Upeka Bee, has been...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Aduhelm Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA,...

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...

Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four...

Ottawa, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The global central nervous system therapeutic market size was calculated at USD 127.29 billion in 2025 and is predicted to attain around USD 285.72 billion...

Global ALS therapeutics market is expected to grow from USD 1.05B in 2025 to USD 1.96B by 2034 at 11.5% CAGR, driven by new therapies and rising worldwide.